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N-cadherin is related to the progression and metastases of several solid carcinomas. However, it was still unclear whether N-cad-     
herin is overexpressed in colorectal malignant tumors that have stronger malignant tendency. In this study, we used immuno-
histochemistry to detect the expression patterns of N-cadherin in both the primary tumors and their normal mucosa tissues of 120 
patients with colorectal cancer. We revealed that N-cadherin was expressed in 78.3% (94/120) of colorectal tumor tissues and in 
only 9.2% (11/120) of paired distant normal mucosa tissues with a significant difference (P=0.000). The low, moderate, and high 
expression of N-cadherin protein was 42.5%, 30.8%, and 26.7%, respectively. N-cadherin overexpression was associated with 
advanced TNM stage, lymph nodes metastasis and distant metastasis (P<0.05). Patients with N-cadherin overexpressed showed 
the obvious lower overall survival rate than those with moderate and low expression, and patients with low expression had a better 
survival rate than those with moderate and high expression (P<0.05). In conclusion, high N-cadherin expression may lead to tu-
mor aggressiveness and metastatic potential in colorectal cancer, and may prove to be a possible prognostic factor. 
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Colorectal cancer is one of the most common malignancies, 
and causes cancer-related deaths ranked third in the word-
worldwide [1]. China, as well as some other Asian countries, 
has experienced a 2–4-fold increase in colorectal cancer 
incidence during the past several decades [2]. The majority 
of patients are diagnosed with advanced stage cancer, which 
is generally resistant to treatment efforts, therefore restrict-
ing further treatment to improve the prognosis. Therefore, 
candidate biomarkers for early detection and prognosis of 
colorectal cancer are urgently needed to early treatment and 
improve survival rate. Thus, candidate biomarkers for early 
detection and prognostication of colorectal cancer are ur-
gently required to guide early treatment and improve sur-
vival rates [3].  
N-cadherin is a potential biomarker that may predict the 
metastasis and prognosis of colorectal cancer. N-cadherin 
was first identified in the brains of mouse embryos, then in 
murine nervous tissues, lens and cardiac muscle [4,5]. N- 
cadherin overexpression has been observed in several car-
cinomas. High expression of N-cadherin in breast cancer 
induces invasion and metastasis [6,7], while reduced N- 
cadherin inhibits tumor cell growth, migration and invasion, 
resulting in a better prognosis in the pancreatic ductal ade-
nocarcinoma mouse model [8]. Expression of N-cadherin is 
also related to metastasis in prostate cancer and increases 
metastases in patients of castration-resistant tumors [9]. 
Increased N-cadherin expression, together with decreased 
expression of E-cadherin, is a prominent characteristic of 
epithelial-mesenchymal transition (EMT), which arises dur-
ing tumor progression; this “cadherin switching” plays an 
important role in the most of tumor cells [10]. EMT process 
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is very important for colorectal cancer. Epithelial mesenchy-
mal proteins, including E-cadherin, LAMC2, beta-catenin and 
cathepsin L, play key roles in the occurrence and develop-
ment of scolorectal cancer [11]. These findings suggest that 
N-cadherin, an epithelial mesenchymal protein, may also 
play a critical role in colorectal cancer; however, its expres-
sion in this cancer remains to be ascertained. In our study, 
we detected the expression of N-cadherin in colorectal tissues 
to clear and definite its relationship with clinicopathological 
characteristics and prognosis of colorectal cancer patients. 
1  Materials and methods 
1.1  Patients and follow-up 
A total of 120 patients with colorectal cancer were enrolled, 
as described in our previous study [12]. All patients were 
confirmed by pathology and underwent radical surgery at 
Peking University People’s Hospital from September 2002 
to April 2004. There were 74 men and 46 women, with a 
mean age of 64.5±12.8 years (range, 26–89 years). Seventy- 
five (62.5%) patients had colon tumors and 45 (37.5%) pa-
tients had rectal tumors. No preoperative chemotherapy or 
radiotherapy was performed. The clinicopathological fea-
tures are listed in Table 1.  
The median survival time of patients was 53.3 months 
(range, 1–78 months). At the end of the study, 43 patients 
died. All the patients were followed up by phone interview 
or direct evaluation until death or December 2008. Our study 
was consented by the Ethics Committee of Peking Univer-
sity People’s Hospital.  
1.2  Tissue samples and tissue microarray  
Circular specimens of 2 mm diameter were from formalin- 
fixed paraffin-embedded colorectal tumor tissues and paired 
distant normal mucosa tissues. The tissues were arranged in 
a new tissue microarray (Beecher Instruments, Microarray 
Technologies, Silver Spring, MD). For the 120 pairs of tu-
mor and distant normal mucosa tissues, 11 tissue microarraies 
were fabricated, each containing 10–12 tumor and normal 
mucosa tissues. In order to control the quality, area of tumor 
should be accounted for 10% of the total at least. Each case 
contains at least two qualified specimens at the microarray. 
1.3  Immunohistochemistry and scoring  
Tissue array sample dissolved in xylene to deparaffinize, 
rehydrated in a graded ethanol, and then treated to antigen 
retrieval by 6.5 mmol/L sodium citrate buffer (pH 6.0). The 
tissues were incubated with sheep polyclonal anti-N-cadherin 
antibody (5 mg/L) (R&D Systems Inc., Minneapolis, MN, 
USA) at room temperature for 2 h. Primary antibodies were 
detected using the Powervision two-step histostaining rea-
gent (Zhongshan Inc., Beijing, China), with PV-9003 as the 
secondary antibody, and detection was performed by dia-
minobenzidine chromogenic reaction. Immunostaining scores 
accorded to the previous method [13]. N-cadherin expres-
sion was graded according to the area and intensity of 
staining. The intensity was classified by the following prin-
ciple: 3, intense staining; 2, moderate staining; 1, mild stain-
ing; 0, no staining. The area was measured as the following 
codex: 3, >60% positively stained; 2, 30%–60% positively 
stained; 1, <30% of cells positively stained; 0, no staining of 
cells in any microscopic fields. The summed score (intensi-
ty+area) of 2 indicated low expression, the score between 
3 and 4 indicated moderate expression, whereas the score 
between 5 and 6 indicated high expression. 
1.4  Statistical analyses  
All data were analyzed using SPSS 16.0 software (SPSS Inc, 
Chicago, IL, USA). The association of N-cadherin expres-
sion with clinicopathological characteristics was counted by 
2 tests. Cumulative survival rate was calculated by the 
Kaplan-Meier curve, and differences of survival rates were 
compared by log-rank test. P values of <0.05 were as statis-
tically significant. 
2  Results 
2.1  N-cadherin expression in tumor and normal  
mucosa tissues 
The expression of N-cadherin was identified by immuno-
histochemistry to appear as the cellular origin and distribu-
tion. N-cadherin staining was negative or weak in paired 
distant normal mucosa tissues (Figure 1), but stronger in 
colorectal cancer tissues. Results of the microarray immuno-
histochemistry showed that the positive staining rate of 
N-cadherin was 78.3% (94/120) in colorectal cancer tissues 
and 9.2% (19/120) in normal mucosa, with a statistically 
significant difference (P=0.000). 
2.2  Clinicopathological significance of N-cadherin  
expression 
Elevated levels of N-cadherin expression in colorectal can-
cer tissues were significantly related to more malignant phe-
notypes, including advanced TNM stage (P=0.009), lymph 
node metastasis (P=0.002) and distant metastasis (P=0.004). 
In contrast, there were no significant differences in N-cad-     
herin expression in colorectal cancer tissues for other clini-
copathological features, including age, gender, site of tumor, 
tumor location, tissue differentiation, depth of wall invasion 
(T-stage) and recurrence (P>0.05).  
2.3  Prognostic implications of N-cadherin expression 
The five-year survival rates of low, moderate, and high  
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Table 1  Relationship of clinicopathological features and N-cadherin expression in 120 colorectal cancer patients 
 
n 
N-cadherin expressiona) 2 P 
Low Mod High 
Tissue     67.108  0.000 
Non-neoplastic samples 120  109  11  0     
Tumor samples  120  51  37  32     
Age     1.996  0.369 
>65 years 63  23  18  19     
65 years 57  28  19  13     
Gender     2.544  0.280 
Male 74  33  19  22     
Female 46  18  18  10     
Size of tumor     2.839  0.242 
>5 cm 35  11  14  10     
5 cm 85  40  23  22     
Location     1.471  0.479 
Colon 75  35  21  19     
Rectum 45  16  16  13     
Differentiation grade     4.646  0.098 
Poor 21  5  7  9     
Moderate or well 99  46  30  23     
TNM staging        
I 11  5  4  2   17.096  0.009 
II 43  23  12  8     
III 44  21  13  10     
IV 22  2  8  12     
Depth of wall invasion        
T1 1  0  1  0   11.605  0.071 
T2 18  12  5  1     
T3 95  38  28  29     
T4 6  1  3  2     
Lymph nodes metastasis      12.247  0.002 
No 56  33  14  9     
Yes 64  18  23  23     
Distant metastasis      10.897  0.004 
M0 96  47  29  20     
M1 24  4  8  12     
Recurrence      2.883  0.237 
No 98  44  31  23      
Yes 22  7  6  9     
a) N-cadherin expression: well, well differentiated; mod, moderately differentiated; poor, poorly differentiated.  
expression of N-cadherin in colorectal cancer patients were 
77.2%, 56.6% and 28.5%, respectively. The mean survival 
time was 66.4±3.4 months in patients with low expression 
of N-cadherin, with a comparison of 49.9±5.1 months for 
those individuals with moderate expression and 30.5±5.5 
months for those with high expression. The survival curves 
proved that the overall survival rates decreased significantly 
with upregulated N-cadherin expression (Figure 2). 
3  Discussion and conclusions 
N-cadherin is located at adherens junctions, where it mediates 
a dynamic contact not only between cells but also between 
matrix and cells [14]. In addition, its cytoplasmic expression 
took part in multiple intracellular signaling pathways [15]. 
Several studies showed that N-cadherin enhanced tumor cell 
motility and promoted invasion and metastasis for lots of 
experimental models of tumor [9]. In this study, we showed 
that N-cadherin expression in human was related to metas-
tasis and prognosis of colorectal cancer.  
First, we found that N-cadherin protein was more highly 
expressed in colorectal tumor than paired distant normal 
mucosa tissues. The positive expression rate of N-cadherin 
in colorectal cancer tissues was 78.3%, which was similar to 
other tumor types. It has been found that N-cadherin is ex-
pressed in 58% of melanoma cell lines [16], 53.6% of breast 
invasive ductal carcinoma, 68.4% of invasive lobular   
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Figure 1  Immunohistochemical staining of N-cadherin expression in colorectal tumors (a), (c), (e), (g) and paired normal mucosa (b), (d), (f), (h). Positive 
staining in tumor: negative (a), weak (c), moderate (e), and strong staining (g); negative or weak staining (b), (d), (f), (h) in distant normal mucosa. Original 
magnification ×100.  
carcinoma and 31.7% of carcinoma in situ [17]. These high 
expression rates in malignant tumors suggest that it may 
play an important role in tumor progression.  
We noted that N-cadherin expression was positively as-
sociated with clinical TNM stage. However, no relationship 
was found between expression of N-cadherin and the depth 
of wall invasion (T-stage). We deduced that the relationship 
of N-cadherin expression and TNM stage was due to lymph 
node metastasis (N-stage) and/or distant metastasis (M-stage). 
As expected, this presumption was proved by our further 
investigations, which demonstrated that N-cadherin expres-
sion was positively associated with lymph node metastasis 
and distant metastasis in a large number of colorectal cancer 
patients. In previous studies, N-cadherin expression was 
thought to have a link with pelvic lymph node invasion and 
little time to skeletal metastasis [18]. High N-cadherin  
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Figure 2  Kaplan-Meier survival curves according to the expression of 
N-cadherin for colorectal cancer patients. High exp, high expression; mod 
exp, moderate expression; low exp, low expression. low exp vs mod exp 
(P=0.035); mod exp vs high exp (P=0.018); low exp vs high exp (P=0.000). 
expression was shown in triple-negative breast cancer with 
lymphatic infiltration [19]. It plays a vital role in metastasis 
of head and neck spindle cell carcinoma [20], and is well 
related to the invasion and lymph node metastasis in squa-
mous cell carcinoma of head and neck region [21]. Con-
versely, a recent study showed that there was no association 
of N-cadherin expression with either nodal or distant me-
tastasis of extrahepatic cholangiocarcinoma [22]. Based on 
the previous findings and our study, we can conclude that 
N-cadherin may promote the metastatic process of colorec-
tal cancer, as well as that of other solid malignant tumors. 
The functional mechanism of N-cadherin in inducing 
metastasis of colorectal cancer is still unclear. Much effort 
in elucidating its biological behavior in various other tumors 
has been made. N-cadherin facilitates the dissociation of 
single cells from the primary tumor [23] and most probably 
renders the cells more motile by homophilic adhesion to 
some other cells [24]. Then, homophilic interactions be-
tween N-cadherin-expressing tissues and cancer cells, such 
as vasculature and stroma, promote transit through the tissue 
and the live of cancer cells in other organs [25]. Knockdown 
of N-cadherin expression leads to decreased cell aggrega-
tion and increased cell migration and invasion [26]. At the 
same time, many genes influence metastasis through regula-
tion of N-cadherin and other EMT participators, such as 
MUC4 [27], WIF1 [28], EIF5A2 [29], and HIF-1alpha [30]. 
Our next study will focus on clarifying the undefined 
mechanism of N-cadherin in colorectal cancer metastasis. 
Most important of all, N-cadherin protein was closely 
correlated with prognosis of colorectal cancer patients; the 
higher the N-cadherin expression, the worse the outcome 
will be for patient survival. It has been found that high ex-
pression of N-cadherin usually means a reduced survival 
time in several malignant tumors, including extrahepatic 
cholangiocarcinoma [22], osteosarcoma [31], urothelial car-
cinoma [32], prostate cancer, and breast cancer [33]. These 
results certify that N-cadherin is a valuable prognostic bi-
omarker of colorectal cancer, as well as in other tumors. 
However, further research should be carried out in multiple 
centers, for our study was merely based on patients attend-
ing a single hospital and included just 120 patients.  
In conclusion, N-cadherin expression was significantly 
associated with TNM stage, lymph node metastasis and 
distant metastasis. It may be a potential biomarker in the 
clinical setting for predicting metastasis and prognosis of 
colorectal cancer. 
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